TY - JOUR
T1 - CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial
T2 - CALGB 150304
AU - Edelman, Martin J.
AU - Hodgson, Lydia
AU - Rosenblatt, Paula Y.
AU - Christenson, Robert H.
AU - Vokes, Everett E.
AU - Wang, Xiaofei
AU - Kratzke, Robert
PY - 2012/4
Y1 - 2012/4
N2 - BACKGROUND:: Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may be associated with response to therapy and survival in non-small-cell lung cancer (NSCLC). As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. METHODS:: Serum CYFRA levels were measured at baseline and after the first cycle of treatment using an electrochemoluminescent assay. Paired specimens were available from 88 patients. The logarithms of the initial concentration and of the difference in concentrations were analyzed for association with overall survival (OS) and failure-free survival (FFS). RESULTS:: Lower baseline CYFRA levels were associated with both longer OS and FFS (p < 0.0001 and p = 0.0003). In addition, larger reductions in CYFRA levels correlated with longer OS and FFS (p = 0.0255 and p = 0.0068). CONCLUSION:: CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined.
AB - BACKGROUND:: Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may be associated with response to therapy and survival in non-small-cell lung cancer (NSCLC). As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. METHODS:: Serum CYFRA levels were measured at baseline and after the first cycle of treatment using an electrochemoluminescent assay. Paired specimens were available from 88 patients. The logarithms of the initial concentration and of the difference in concentrations were analyzed for association with overall survival (OS) and failure-free survival (FFS). RESULTS:: Lower baseline CYFRA levels were associated with both longer OS and FFS (p < 0.0001 and p = 0.0003). In addition, larger reductions in CYFRA levels correlated with longer OS and FFS (p = 0.0255 and p = 0.0068). CONCLUSION:: CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined.
KW - CYFRA
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84863368614&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000301866500004&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1097/JTO.0b013e31824a8db0
DO - 10.1097/JTO.0b013e31824a8db0
M3 - Article
C2 - 22425913
SN - 1556-0864
VL - 7
SP - 649
EP - 654
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 4
ER -